Evidence map›Paper›PMID 26491285›Full record

ArticleInternational journal of nanomedicine2015

Cytotoxicity of various types of gold-mesoporous silica nanoparticles in human breast cancer cells.

Guomu Liu, Qiongshu Li, Weihua Ni, Nannan Zhang, Xiao Zheng, Yingshuai Wang, Dan Shao, Guixiang Tai

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Nanocarrier-Based Drug Delivery for Melanoma Therapeutics.International journal of molecular sciences · 2021
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Guomu LiuDepartment of Immunology, College of Basic Medical Sciences, Jilin University, Changchun, People's Republic of China.
Qiongshu LiDepartment of Immunology, College of Basic Medical Sciences, Jilin University, Changchun, People's Republic of China ; Shenzhen Beike Cell Engineering Research Institute, Yuanxing Science and Technology Building, Nanshan, Shenzhe, People's Republic of China.
Weihua NiDepartment of Immunology, College of Basic Medical Sciences, Jilin University, Changchun, People's Republic of China.
Nannan ZhangDepartment of Immunology, College of Basic Medical Sciences, Jilin University, Changchun, People's Republic of China.
Xiao ZhengDepartment of Pharmacology, Nanomedicine Engineering Laboratory of Jilin Province, College of Basic Medical Sciences, Jilin University, Changchun, People's Republic of China.
Yingshuai WangState Key Laboratory on Integrated Optoelectronics, College of Electronic Science and Engineering, Jilin University, Changchun, People's Republic of China.
Dan ShaoDepartment of Pharmacology, Nanomedicine Engineering Laboratory of Jilin Province, College of Basic Medical Sciences, Jilin University, Changchun, People's Republic of China.
Guixiang TaiDepartment of Immunology, College of Basic Medical Sciences, Jilin University, Changchun, People's Republic of China.
Jilin University · CNBeike Biotechnology (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, gold nanoparticles (AuNPs) have shown promising biological applications due to their unique electronic and optical properties. However, the potential toxicity of AuNPs remains a major hurdle that impedes their use in clinical settings. Mesoporous silica is very suitable for the use as a coating material for AuNPs and might not only reduce the cytotoxicity of cetyltrimethylammonium bromide-coated AuNPs but might also facilitate the loading and delivery of drugs. Herein, three types of rod-like gold-mesoporous silica nanoparticles (termed bare AuNPs, core-shell Au@mSiO2NPs, and Janus Au@mSiO2NPs) were specially designed, and the effects of these AuNPs on cellular uptake, toxic behavior, and mechanism were then systematically studied. Our results indicate that bare AuNPs exerted higher toxicity than the Au@mSiO2NPs and that Janus Au@mSiO2NPs exhibited the lowest toxicity in human breast cancer MCF-7 cells, consistent with the endocytosis capacity of the nanoparticles, which followed the order, bare AuNPs > core-shell Au@mSiO2NPs > Janus Au@mSiO2NPs. More importantly, the AuNPs-induced apoptosis of MCF-7 cells exhibited features that were characteristic of intracellular reactive oxygen species (ROS) generation, activation of c-Jun-N-terminal kinase (JNK) phosphorylation, an enhanced Bax-to-Bcl-2 ratio, and loss of the mitochondrial membrane potential. Simultaneously, cytochrome c was released from mitochondria, and the caspase-3/9 cascade was activated. Moreover, both ROS scavenger (N-acetylcysteine) and JNK inhibitor (SP600125) partly blocked the induction of apoptosis in all AuNPs-treated cells. Taken together, these findings suggest that all AuNPs induce apoptosis through the ROS-/JNK-mediated mitochondrial pathway. Thus, Janus Au@mSiO2NPs exhibit the potential for applications in biomedicine, thus aiding the clinical translation of AuNPs.

Indexed as

AnimalsApoptosisBrainBreast NeoplasmsCaspase 3Caspase 9Cells, CulturedCytochromes cEndothelium, VascularFemaleGene Expression ProfilingGoldHumansMAP Kinase Signaling SystemMCF-7 CellsMembrane Potential, MitochondrialCaspase 3Caspase 9Cytochromes cGoldReactive Oxygen SpeciesSilicon Dioxidec-Jun-N-terminal kinasecytotoxicitygold-mesoporous silica Janus nanoparticlesgold nanoparticlesmitochondrial apoptosisreactive oxygen species

Identifiers

PMID26491285
PMCPMC4598223
OpenAlexW2120082355

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.